Factor analysis is a powerful tool used for the analysis of dynamic studies. One of the major drawbacks of factor analysis of dynamic structures (FADS) is that the solution is not mathematically unique when only nonnegativity constraints are used to determine factors and factor coefficients. In this paper, a method to correct for ambiguous FADS solutions has been developed. A nonambiguous solution (to within certain scaling factors) is obtained by constructing and minimizing a new objective function. The most common objective function consists of a least squares term that when minimized with nonnegativity constraints, forces agreement between the applied factor model and the measured data. In our method, this objective function is modified by adding a term that penalizes multiple components in the images of the factor coefficients. Due to nonuniqueness effects, these factor coefficients consist of more than one physiological component. The technique was tested on computer simulations, an experimental canine cardiac study using 99mTc-teboroxime, and a patient planar 99mTc-MAG3 renal study. The results show that the technique works well in comparison to the truth in computer simulations and to region of interest (ROI) measurements in the experimental studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/42.996340 | DOI Listing |
Acc Chem Res
January 2025
Molecular Sensing and Imaging Center, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
ConspectusIons are the crucial signaling components for living organisms. In cells, their transportation across pore-forming membrane proteins is vital for regulating physiological functions, such as generating ionic current signals in response to target molecule recognition. This ion transport is affected by confined interactions and local environments within the protein pore.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
January 2025
Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Objective: Programmed Death-Ligand 1 (PD-L1) and Cytotoxic T Lymphocyte -Associated Antigen-4 (CTLA-4) are presently considered as prognostic markers and therapeutic targets in numerous human malignancies. The goal of this study was to determine whether PD-L1 and CTLA-4 might be used to predict patients' survival in Triple Negative Breast Cancer (TNBC).
Methods: This retrospective cohort study analyzed 100 primary TNBC cases that had surgical resection at the Oncology Center of Mansoura University (OCMU), Faculty of Medicine, Egypt.
Asian Pac J Cancer Prev
January 2025
Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada Sekip Utara II, 55281 Yogyakarta, Indonesia.
Objective: Programmed cell death-1 (PD-1, encoded by PDCD1) regulatory network participates in glioblastoma multiforme development. However, such a network in trastuzumab-resistant human epidermal growth factor receptor 2-positive (HER2+) breast cancer remains to be determined. Accordingly, this study was aimed to explore the PD-1 regulatory network responsible for the resistance of breast cancer cells to trastuzumab through a bioinformatics approach.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
January 2025
Adhiparasakthi Dental College and Hospital, Melmaruvathur, India.
Background: Angiogenesis, the formation of new blood vessels from preexisting ones via capillary sprouting, is a crucial process in tumor growth and metastasis. As a tumor's angiogenic capacity increases, its microvasculature, measured by micro vessel density (MVD), also increases. This study aims to evaluate the expression of Vascular Endothelial Growth Factor (VEGF) and CD34 in oral epithelial dysplasia and oral squamous cell carcinoma through immunohistochemical methods.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
January 2025
Division of Hematology and Medical Oncology, Udayana University, Prof. I.G.N.G Ngoerah General, Badung, Bali, Indonesia.
Objectives: To explore the significance of diminished CD3/CD8 and CD3/CDR45RO immunoscores, as well as elevated FOXP3 expression, as potential risk factors for unfavorable responses to neoadjuvant chemotherapy among patients with triple-negative breast cancer (TNBC).
Methods: A case-control study was conducted across two hospitals (a public and a private facility) from August 1st, 2021, to August 31st, 2022. The study population comprised patients diagnosed with the TNBC subtype, with available paraffin blocks from biopsy procedures.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!